ProxyMiner / Company

Medtronic plcMDT

Latest proxy: 2025 · view on SEC ↗ · CIK 0001613103

↓ Export PDF

← All companies

CEO total pay

$21,240,058

Geoffrey S. Martha · 2025

Say on pay

Not disclosed

Use Ask for the underlying narrative

CEO pay ratio

CD&A

309 to 1

Median employee: $68,770

Compensation committee

CD&A

Compensation and Talent Committee

Per the latest proxy

Filings indexed: 2 · 2025 · 2024

Executive pay

What did they pay them?

From the Summary Compensation Table. Pay mix and YoY are computed from these rows.

Executive	Role	TotalYoY	Pay mix	Salary	Stock	Cash incentive	Other
Geoffrey S. Martha2025 compensation	Chairman and Chief Executive Officer	$21,240,058↑ 6%	91% at-risk	$1,350,000	$12,625,000	$1,883,250	$581,443
Karen L. Parkhill2025 compensation	Former Executive Vice President and Chief Financial Officer	$270,679↓ 97%	0% at-risk	$262,856	—	—	$7,823
Sean M. Salmon2025 compensation	Former EVP & President, Cardiovascular Portfolio	$8,396,597↑ 28%	88% at-risk	$884,654	$4,537,157	$823,050	$43,719
Brett A. Wall2025 compensation	EVP & President, Neuroscience Portfolio	$8,121,213↑ 26%	86% at-risk	$774,519	$4,537,157	$720,750	$363,656
Gregory L. Smith2025 compensation	EVP Enterprise Operations	$8,083,981↑ 5%	88% at-risk	$894,560	$4,537,157	$832,350	$94,784
Thierry Piéton2025 compensation	Named executive officer	$5,212,448	95% at-risk	$138,517	$4,190,625	$141,975	$141,274
Gary L. Corona2025 compensation	Named executive officer	$3,795,248	82% at-risk	$466,346	$3,089,088	—	$214,812

Pay mix: base cash incentive equity other

Add to peer comparison →Year-over-year diff →

CD&A excerpt

Compensation discussion & analysis

Opening passage of the loaded filing's CD&A. Use Ask below to query the full text with citations.

The following executive compensation discussion and analysis describes the principles underlying our executive compensation policies and decisions as well as the material elements of compensation for our named executive officers. Medtronic’s named executive officers for fiscal year 2025 were: •Geoffrey S. Martha, Chairman and Chief Executive Officer •Thierry Piéton, Executive Vice President and Chief Financial Officer •Sean M. Salmon, Former Executive Vice President, President Cardiovascular Portfolio •Brett A. Wall, Executive Vice President, President Neuroscience Portfolio •Gregory L. Smith, Executive Vice President, Enterprise Operations •Gary L. Corona, Former SVP Corporate Finance, (Former Interim Chief Financial Officer) •Karen L. Parkhill, Former Executive Vice President and Chief Financial Officer Thierry Piéton was hired on March 3, 2025 and replaced Karen L. Parkhill who resigned from the Company effective August 2, 2024. Gary L. Corona served as Interim Chief Financial Officer from August 3, 2024 through March 2, 2025, and resigned from the Company effective March 28, 2025. For purposes of this Compensation Discussion and Analysis and the related disclosures that follow,…

Read the full CD&A on SEC.gov ↗

Governance

Policy guardrails

hedging
prohibited
“The policy also prohibits our NEOs (along with others) from purchasing Medtronic securities on margin, borrowing against Medtronic securities held in a margin account or hedging or pledging Medtronic securities as collat…”
pledging
prohibited
“The policy also prohibits our NEOs (along with others) from purchasing Medtronic securities on margin, borrowing against Medtronic securities held in a margin account or hedging or pledging Medtronic securities as collat…”
clawback
present
“INCENTIVE COMPENSATION FORFEITURE (“CLAWBACK”)”
stock ownership guidelines
present
“stock ownership guidelines that require our CEO to maintain ownership of stock equal to six times annual base salary, and other NEOs to maintain ownership of stock equal to three times annual base salary”
change in control
CHANGE OF CONTROL POLICY
“CHANGE OF CONTROL POLICY”
compensation consultant
independent
“Independent Compensation Consultant”
compensation committee
Compensation and Talent Committee
“Compensation and Talent Committee Report”

Performance markers

Metric facts

revenue
$33.5 billion
“the greatest possible reliability and quality in our products.” PAY FOR PERFORMANCE Fiscal Year 2025 Financial Performance Summary In fiscal year 2025, the underlying fundamentals of the Company were strong, and getting …”
operating income
—
“communicated to shareholders. •The Compensation and Talent Committee retains discretionary authority to override any incentive plan’s formulaic outcome in the event of unforeseen circumstances. For example, controlling f…”
time equity mix
93%
“Actual compensation reflects 93% FY25 MIP payout based upon financial, team and individual performance and the market value of stock options, time-based RSUs and target performance share units based on the year end (Apri…”
ceo pay ratio
309 to 1
“was $21,240,058 as reported in the “Total” column of the Summary Compensation Table and the annual total compensation for our median employee was $68,770 calculated in accordance with the rules applicable to the Summary …”
median employee compensation
$68,770
“population excluding our CEO, and the ratio of annual total compensation for our CEO to the annual total compensation for our median employee. For the fiscal year ended April 25, 2025, the annual total compensation for o…”

Ask

Anything about Medtronic plc’s 2025 proxy

Answers are grounded in the loaded filing and cite specific artifacts. Bring your own free Google AI Studio key.

Loading the Ask interface…